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COMPARING THE NEUROTOXICITY OF THE CANCER 
DRUGS CISPLATIN AND OXALIPLATIN 
Dan Barkmeier and Anthony Windebank* 
Department of Biology, Illinois Wesleyan University 
Department of Molecular Neuroscience, Mayo Clinic 
Cisplatin is a platinum-based drug that has been used to successfully treat cancer since 
the 1970s, especially testicular and ovarian cancer. Cisplatin acts by binding to DNA and 
interfering with DNA replication, which most significantly affects rapidly dividing cells 
like cancer. However, the dosage that can be given to patients is limited by cisplatin's  
damage to the dorsal root ganglia, which are responsible for somatic sensory. A variety 
of similar platinum drugs have therefore been tested for less damaging neurotoxicity 
profiles. One of these compounds, oxaliplatin, was recently approved for treatment of 
colorectal cancer. Relatively little is known about its exact mechanism of action and 
neurotoxicity though. The goal of this project was to compare the neurotoxicity of 
cisplatin versus oxaliplatin and to further characterize the mechanism of oxaliplatin 
action. Results are not definite yet, but oxaliplatin causes apoptosis just like cisplatin, 
seems to cause less neuron cell death at equimolar concentrations, and both binds to and 
releases from neuron cell DNA more slowly than cisplatin. 
